Overview

A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®

Status:
Withdrawn

Trial end date:
2016-06-01

Target enrollment:

Participant gender:

Summary

A pilot study to evaluate the impact of Lotemax® Gel (loteprednol etabonate ophthalmic gel 0.5%) on the initiation of Restasis® (cyclosporine ophthalmic emulsion 0.05%) therapy in subjects with dry eye.

Phase:

Phase 4

Details

Lead Sponsor:

Edward Holland, MD

Treatments:

Cyclosporine
Cyclosporins
Loteprednol Etabonate
Lubricant Eye Drops